AOD-9604

Common side effects:

• Injection site redness or irritation
• Mild headaches
• Flushing or warmth in the face
• Temporary fatigue or lethargy
• Upset stomach or mild nausea

Rare or serious side effects:

• Allergic reactions at the injection site
• Palpitations or rapid heartbeat
• Dizziness upon standing
• Unexplained joint stiffness

Lipolytic activation is the primary mechanism by which the AOD-9604 peptide exerts its effects, specifically targeting beta-3 adrenergic receptors to stimulate the breakdown of triglycerides into free fatty acids. This targeted action mimics the natural fat-burning pathways of human growth hormone but remains isolated to adipose tissue, preventing systemic endocrine disruption.

Inhibition of lipogenesis further enhances its efficacy by preventing the body from converting dietary carbohydrates and lipids into new fat stores. Because it lacks the specific amino acid sequences responsible for binding to the hGH receptor that triggers IGF-1 release, AOD-9604 does not promote cellular growth or alter insulin sensitivity, making it highly specific for metabolic regulation.

Discovery and development of AOD-9604 began in the late 1990s by researchers at Monash University in Australia, who sought to identify the specific region of the human growth hormone molecule responsible for fat metabolism. They successfully isolated the C-terminal fragment (amino acids 176-191) and modified it with an additional tyrosine residue to stabilize the molecule, creating a potent synthetic peptide.

Regulatory milestones include extensive clinical trials by Metabolic Pharmaceuticals in the early 2000s, which investigated its potential as a mainstream anti-obesity drug Bayés M et al., 2003. Although it reached Phase IIb human clinical trials and demonstrated an excellent safety profile, it is currently designated as a research-only chemical and is actively monitored in sports doping controls Cox HD et al., 2015.